The Experts below are selected from a list of 12258 Experts worldwide ranked by ideXlab platform
Gerald L. Klein - One of the best experts on this subject based on the ideXlab platform.
-
serum derived bovine immunoglobulin protein isolate postulated mechanism of action for management of Enteropathy
Clinical and Experimental Gastroenterology, 2014Co-Authors: Bryon W Petschow, Eric M. Weaver, Bruce Burnett, Audrey L. Shaw, Gerald L. KleinAbstract:The health and performance of the gastrointestinal tract is influenced by the interaction of a variety of factors, including diet, nutritional status, genetics, environment, stress, the intestinal microbiota, immune status, and gut barrier. Disruptions in one or more of these factors can lead to Enteropathy or intestinal disorders that are known to occur in concert with certain disease states or conditions such as irritable bowel syndrome or human immunodeficiency virus (HIV) infection. Nutritional support in the form of a medical food along with current therapies could help manage the adverse effects of Enteropathy, which include effects on nutrient digestion, absorption, and metabolism, as well as utilization of nutrients from foodstuffs. Numerous studies have demonstrated that oral administration of plasma- or serum-derived protein concentrates containing high levels of immunoglobulins can improve weight management, normalize gut barrier function, and reduce the severity of Enteropathy in animals. Recent trials in humans provide preliminary evidence that a serum-derived bovine immunoglobulin/protein isolate is safe and improves symptoms, nutritional status, and various biomarkers associated with Enteropathy in patients with HIV infection or diarrhea-predominant irritable bowel syndrome. This review summarizes data from preclinical and clinical studies with immunoglobulin-containing plasma/serum protein concentrates, with a focus on the postulated mode of action of serum-derived bovine immunoglobulin/protein isolate for patients with Enteropathy.
Ki Baik Hahm - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of human placenta derived mesenchymal stem cells on radiation Enteropathy along with proteomic biomarkers predicting a favorable response
Stem Cell Research & Therapy, 2017Co-Authors: Youngmin Han, Jongmin Park, Yongsoo Choi, Hee Jin, Yunsil Lee, Nayoung Han, Hookeun Lee, Ki Baik HahmAbstract:Radiation Enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation Enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. We challenged a radiation-induced Enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. hPDSCs significantly improved the outcome of mice induced with either radiation Enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR-induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced Enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation Enteropathy. hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation Enteropathy.
-
The efficacy of human placenta-derived mesenchymal stem cells on radiation Enteropathy along with proteomic biomarkers predicting a favorable response
BMC, 2017Co-Authors: Youngmin Han, Jongmin Park, Yongsoo Choi, Hee Jin, Yunsil Lee, Nayoung Han, Hookeun Lee, Ki Baik HahmAbstract:Abstract Background Radiation Enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation Enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. Methods We challenged a radiation-induced Enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. Results hPDSCs significantly improved the outcome of mice induced with either radiation Enteropathy or lethal radiation syndrome (P
Bryon W Petschow - One of the best experts on this subject based on the ideXlab platform.
-
serum derived bovine immunoglobulin protein isolate postulated mechanism of action for management of Enteropathy
Clinical and Experimental Gastroenterology, 2014Co-Authors: Bryon W Petschow, Eric M. Weaver, Bruce Burnett, Audrey L. Shaw, Gerald L. KleinAbstract:The health and performance of the gastrointestinal tract is influenced by the interaction of a variety of factors, including diet, nutritional status, genetics, environment, stress, the intestinal microbiota, immune status, and gut barrier. Disruptions in one or more of these factors can lead to Enteropathy or intestinal disorders that are known to occur in concert with certain disease states or conditions such as irritable bowel syndrome or human immunodeficiency virus (HIV) infection. Nutritional support in the form of a medical food along with current therapies could help manage the adverse effects of Enteropathy, which include effects on nutrient digestion, absorption, and metabolism, as well as utilization of nutrients from foodstuffs. Numerous studies have demonstrated that oral administration of plasma- or serum-derived protein concentrates containing high levels of immunoglobulins can improve weight management, normalize gut barrier function, and reduce the severity of Enteropathy in animals. Recent trials in humans provide preliminary evidence that a serum-derived bovine immunoglobulin/protein isolate is safe and improves symptoms, nutritional status, and various biomarkers associated with Enteropathy in patients with HIV infection or diarrhea-predominant irritable bowel syndrome. This review summarizes data from preclinical and clinical studies with immunoglobulin-containing plasma/serum protein concentrates, with a focus on the postulated mode of action of serum-derived bovine immunoglobulin/protein isolate for patients with Enteropathy.
Youngmin Han - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of human placenta derived mesenchymal stem cells on radiation Enteropathy along with proteomic biomarkers predicting a favorable response
Stem Cell Research & Therapy, 2017Co-Authors: Youngmin Han, Jongmin Park, Yongsoo Choi, Hee Jin, Yunsil Lee, Nayoung Han, Hookeun Lee, Ki Baik HahmAbstract:Radiation Enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation Enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. We challenged a radiation-induced Enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. hPDSCs significantly improved the outcome of mice induced with either radiation Enteropathy or lethal radiation syndrome (P < 0.01). hPDSCs exerted inhibitory actions on inflammatory cytokines, the re-establishment of epithelium homeostasis was completed with increasing endogenous restorative processes as assessed with increased levels of proliferative markers in the hPDSCs group, and a significant inhibition of IR-induced apoptosis. The preservation of cells expressing lysozyme, and Musashi-1 were significantly increased in the hPDSC treatment group. Both preventive and therapeutic efficacies of hPDSCs were noted against IR-induced Enteropathy. Label-free quantification was used to identify biomarkers which predict favorable responses after hPDSC treatment, and finally glutathione S-transferase-mu type, interleukin-10, and peroxiredoxin-2 were validated as proteomic biomarkers predicting a favorable response to hPDSCs in radiation Enteropathy. hPDSCs may be a useful prophylactic and therapeutic cell therapy for radiation Enteropathy.
-
The efficacy of human placenta-derived mesenchymal stem cells on radiation Enteropathy along with proteomic biomarkers predicting a favorable response
BMC, 2017Co-Authors: Youngmin Han, Jongmin Park, Yongsoo Choi, Hee Jin, Yunsil Lee, Nayoung Han, Hookeun Lee, Ki Baik HahmAbstract:Abstract Background Radiation Enteropathy is a common complication in patients with abdominopelvic cancer, but no treatment has yet been established. Stem cell therapy may be a viable therapeutic option because intestinal stem cells are highly vulnerable to ionizing radiation (IR) and stem cell loss explains its intractability to general treatment. Here, we investigated either prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation Enteropathy and could identify biomarkers predicting a favorable response to stem cell therapy. Methods We challenged a radiation-induced Enteropathy model with hPDSCs. After sacrifice, we checked the gross anatomy of small intestine, histology gross, and analyzed that, accompanied with molecular changes implicated in this model. Results hPDSCs significantly improved the outcome of mice induced with either radiation Enteropathy or lethal radiation syndrome (P
Audrey L. Shaw - One of the best experts on this subject based on the ideXlab platform.
-
serum derived bovine immunoglobulin protein isolate postulated mechanism of action for management of Enteropathy
Clinical and Experimental Gastroenterology, 2014Co-Authors: Bryon W Petschow, Eric M. Weaver, Bruce Burnett, Audrey L. Shaw, Gerald L. KleinAbstract:The health and performance of the gastrointestinal tract is influenced by the interaction of a variety of factors, including diet, nutritional status, genetics, environment, stress, the intestinal microbiota, immune status, and gut barrier. Disruptions in one or more of these factors can lead to Enteropathy or intestinal disorders that are known to occur in concert with certain disease states or conditions such as irritable bowel syndrome or human immunodeficiency virus (HIV) infection. Nutritional support in the form of a medical food along with current therapies could help manage the adverse effects of Enteropathy, which include effects on nutrient digestion, absorption, and metabolism, as well as utilization of nutrients from foodstuffs. Numerous studies have demonstrated that oral administration of plasma- or serum-derived protein concentrates containing high levels of immunoglobulins can improve weight management, normalize gut barrier function, and reduce the severity of Enteropathy in animals. Recent trials in humans provide preliminary evidence that a serum-derived bovine immunoglobulin/protein isolate is safe and improves symptoms, nutritional status, and various biomarkers associated with Enteropathy in patients with HIV infection or diarrhea-predominant irritable bowel syndrome. This review summarizes data from preclinical and clinical studies with immunoglobulin-containing plasma/serum protein concentrates, with a focus on the postulated mode of action of serum-derived bovine immunoglobulin/protein isolate for patients with Enteropathy.